Pharmaceutical

Verona Pharma’s ensifentrine inches closer to approval decision in COPD

The agency has set a PDUFA target action date to June 2024, with no current plans for an advisory meeting in the works.

Sep 11, 2023 - 20:00
Verona Pharma’s ensifentrine inches closer to approval decision in COPD
The agency has set a PDUFA target action date to June 2024, with no current plans for an advisory meeting in the works.
Read the original article

Tags:

Previous Article

Pharmaceutical Technology Excellence Awards 2023: Viedoc

Next Article

Why prefilled vial capacity is key to a competitive edge in pharmaceuticals manu...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds

STAT+: More drug and device patents were invalidated fo...

Nov 15, 2023

STAT+: FDA panel votes against high blood pressure device from Medtronic, but lends support to ReCor Medical’s

STAT+: FDA panel votes against high blood pressure devi...

Aug 23, 2023

US Election: In close race, tiny Senate majority, not President, will hold power

US Election: In close race, tiny Senate majority, not P...

Nov 5, 2024